Evofem Biosciences Stock Price To Sales
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem Biosciences fundamentals help investors to digest information that contributes to Evofem Biosciences' financial success or failures. It also enables traders to predict the movement of Evofem OTC Stock. The fundamental analysis module provides a way to measure Evofem Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evofem Biosciences otc stock.
Evofem |
Evofem Biosciences OTC Stock Price To Sales Analysis
Evofem Biosciences' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Evofem Biosciences Price To Sales | 0.42 X |
Most of Evofem Biosciences' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Evofem Biosciences has a Price To Sales of 0.42 times. This is 98.04% lower than that of the Pharmaceuticals sector and 99.57% lower than that of the Health Care industry. The price to sales for all United States stocks is 96.32% higher than that of the company.
Evofem Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in price to sales category among its peers.
Evofem Fundamentals
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 8.24 M | ||||
| Gross Profit | 4.19 M | ||||
| EBITDA | (204.14 M) | ||||
| Net Income | (205.19 M) | ||||
| Cash And Equivalents | 19.89 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 125.74 M | ||||
| Debt To Equity | 8.72 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (146.67 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (19.01) X | ||||
| Target Price | 2.9 | ||||
| Number Of Employees | 119 | ||||
| Beta | -1.25 | ||||
| Market Capitalization | 6.41 M | ||||
| Total Asset | 42.51 M | ||||
| Retained Earnings | (526.68 M) | ||||
| Working Capital | 3.78 M | ||||
| Current Asset | 16.39 M | ||||
| Current Liabilities | 12.61 M | ||||
| Z Score | -30.0 | ||||
| Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |